Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07538583 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
A Phase 2 study, sponsored by Quoin Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT07538583 is a Phase 2 study that is actively recruiting participants, run by Quoin Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT07538583, a Phase 2 study, is actively recruiting participants, sponsored by Quoin Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.
Interventions
- DRUG QRX003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-03-19 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07538583
The ClinicalTrials.gov registry entry for NCT07538583 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quoin Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which QRX003 is the first listed.
NCT07538583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07538583 about?
NCT07538583 is a clinical study titled "Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome". This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body S...
What is the current status of trial NCT07538583?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2026-03-19. Estimated completion is 2027-03-31.
What interventions are being tested in trial NCT07538583?
The interventions under investigation include: QRX003 (DRUG).
Who is sponsoring clinical trial NCT07538583?
This trial is sponsored by Quoin Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.